Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exercise certain existing Series E and Series F warrants to purchase up to approximately 4.36 million of the company's American Depositary Shares (ADS).
Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesProceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant FundingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX),